methylphenidate has been researched along with Lassitude in 99 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Methylphenidate is a psychostimulant drug used to treat fatigue in patients with advanced cancer, for which there is no gold standard of treatment." | 9.51 | Improved cancer-related fatigue in a randomised clinical trial: methylphenidate no better than placebo. ( Centeno, C; Cuervo, MA; De Santiago, A; Gagnon, B; Gandara, A; Portela, MA; Ramos, D; Rojí, R; Salgado, E; Sanz, A, 2022) |
| "Methylphenidate, modafinil, and amantadine are commonly prescribed medications for alleviating fatigue in multiple sclerosis; however, the evidence supporting their efficacy is sparse and conflicting." | 9.41 | Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. ( Aljarallah, S; Auvray, C; Cordano, C; Creasman, J; Jin, C; Krysko, K; Manguinao, M; McCulloch, C; Morris, B; Mowry, E; Nourbakhsh, B; Revirajan, N; Rutatangwa, A; Waubant, E, 2021) |
| "To evaluate the efficacy of methylphenidate as needed for the management of fatigue in patients with advanced cancer." | 9.34 | Methylphenidate as Needed for Fatigue in Patients With Advanced Cancer. A Prospective, Double-Blind, and Placebo-Controlled Study. ( Groenvold, M; Lund, L; Pedersen, L; Petersen, MA; Sjogren, P, 2020) |
| "The study is a randomized, placebo-controlled, crossover, four-sequence, four-period, double-blind, multicenter trial of three commonly used medications for the treatment of MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in fatigued subjects with MS." | 9.27 | Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial. ( Nourbakhsh, B; Revirajan, N; Waubant, E, 2018) |
| "The Fatigue and Sarcoidosis-Treatment with Methylphenidate study is a randomised, controlled, parallel-arm and feasibility trial of methylphenidate for the treatment of sarcoidosis-associated fatigue." | 9.24 | Feasibility study of a randomised controlled trial to investigate the treatment of sarcoidosis-associated fatigue with methylphenidate (FaST-MP): a study protocol. ( Atkins, C; Clark, AB; Fordham, R; Jones, AP; Stockl, A; Wilson, AM, 2017) |
| "To investigate whether methylphenidate can alleviate fatigue, as measured by the Functional Assessment of Cancer Therapy: Fatigue subscale, in men with prostate cancer (PCa) treated with a luteinizing hormone-releasing hormone (LHRH) for a minimum of 6 months, and to assess changes in global fatigue and quality of life (QoL) as measured by the Bruera Global Fatigue Severity Scale (BFS) and the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), respectively." | 9.20 | Phase II, randomised, double-blind, placebo-controlled trial of methylphenidate for reduction of fatigue levels in patients with prostate cancer receiving LHRH-agonist therapy. ( Alibhai, SM; Bhatt, JR; Chahin, R; Fleshner, NE; Hersey, KM; Richard, PO, 2015) |
| "Modafinil had no effect on cancer-related fatigue and should not be prescribed outside a clinical trial setting." | 9.19 | Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. ( Bahadori, R; Bates, N; Benepal, T; Blackhall, F; Dutton, S; Fife, K; O'Brien, M; Spathis, A; Stone, P; Wee, B; Wharton, R, 2014) |
| "REASON FOR THE STUDY: Studies on methylphenidate for cancer-related fatigue showed conflicting results." | 9.19 | Use of methylphenidate for the management of fatigue in Chinese patients with cancer. ( Kwok, AO; Lam, PT; Law, M; Leung, TW; Liu, RK; Ng, KH; Siu, SW; Soong, IS; Wong, KH, 2014) |
| "To evaluate the response of fatigue and depression in patients with advanced illness to titrated doses of methylphenidate (MP) as compared with placebo." | 9.16 | Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial. ( Brazeau, DA; Brazeau, GA; Donnelly, JP; Drake, J; Kerr, CW; Milch, RA; Skretny, JA, 2012) |
| " Using an area under the serum concentration-time curve analysis, there was no evidence that methylphenidate, as compared with placebo, improved the primary end point of cancer-related fatigue in this patient population (P = ." | 9.14 | Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. ( Ali, A; Atherton, PJ; Barton, D; Dakhil, SR; Duane, SF; Griffin, PC; Johnson, DB; Loprinzi, CL; Moraska, AR; Silberstein, PT; Sloan, JA; Sood, A; Suh, JJ, 2010) |
| "This 6-week, randomized, double-blind, placebo-controlled design evaluated the efficacy of methylphenidate to treat fatigue in prostate cancer patients." | 9.14 | Methylphenidate for fatigue in ambulatory men with prostate cancer. ( Arauz, G; Breitbart, W; Morris, M; Nelson, C; O'Shea, N; Rosenfeld, B; Roth, AJ; Scher, H; Slovin, S, 2010) |
| "Fatigue scores fell significantly during methylphenidate intake in comparison with baseline (mean difference: -0." | 9.12 | Does methylphenidate reduce the symptoms of chronic fatigue syndrome? ( Blockmans, D; Bobbaers, H; Persoons, P; Van Houdenhove, B, 2006) |
| "This study suggests that women with breast cancer who are suffering from moderate to severe fatigue may benefit from methylphenidate." | 9.12 | A phase II study of methylphenidate for the treatment of fatigue. ( Bhatia, S; Daggy, J; Einhorn, L; Hanna, A; Hanna, N; Mayer, ML; Monahan, P; Sledge, G, 2006) |
| "To evaluate the effectiveness of patient-controlled methylphenidate as compared with placebo in cancer patients with fatigue, as measured by the Functional Assessment for Chronic Illness Therapy-Fatigue (FACIT-F)." | 9.12 | Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. ( Bruera, E; Driver, L; Palmer, JL; Shen, L; Valero, V; Willey, J; Zhang, T, 2006) |
| "To assess the effects of patient-controlled methylphenidate for cancer-related fatigue." | 9.10 | Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. ( Barnes, EA; Bruera, E; Driver, L; Escalante, C; Palmer, JL; Shen, L; Willey, J, 2003) |
| "In the absence of definitive evidence of effectiveness, trials of low-dose methylphenidate in medically ill adults with depression, fatigue, or apathy, with monitoring for response and adverse effects, are appropriate." | 8.85 | Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults. ( Hardy, SE, 2009) |
| "Single therapy with methylphenidate or American ginseng contributes to the reduction in cancer-related fatigue (CRF) with different pharmacologic mechanisms and is relatively safe." | 7.88 | Single Institute Experience With Methylphenidate and American Ginseng in Cancer-Related Fatigue. ( Chang, YD; Davis, M; Kim, R; Oberoi-Jassal, R; Portman, D; Rajasekhara, S; Smith, J, 2018) |
| "To review recent evidence on the efficacy and safety of methylphenidate as a symptomatic treatment of patients with cancer-related fatigue (CRF)." | 7.85 | The use of methylphenidate to relieve fatigue. ( Centeno, C; Rojí, R, 2017) |
| "To examine the effect of exercise and methylphenidate on fatigue, functional ability, and cognitive function in patients with melanoma." | 7.71 | Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. ( Masood, N; Schwartz, AL; Thompson, JA, 2002) |
| " His progressively worsening excessive daytime sleepiness (EDS) was treated with methylphenidate hydrochloride." | 7.71 | Methylphenidate hydrochloride for excessive daytime sleepiness in a patient with myotonic dystrophy. ( Aizawa, C; Hirata, K; Miyamoto, M; Miyamoto, T; Suga, T; Takekawa, H, 2002) |
| "Fatigue is common in life-limiting cancer." | 6.80 | The Effect of Methylphenidate on Fatigue in Advanced Cancer: An Aggregated N-of-1 Trial. ( Carmont, SA; Currow, DC; Good, P; Hardy, JR; Mitchell, GK; Nikles, CJ; Schluter, PJ; Senior, HE, 2015) |
| "Methylphenidate dose was 5 mg every 2 hours as needed up to 20 mg per day." | 6.78 | Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial. ( Allo, JA; Bruera, E; Cohen, MZ; Frisbee-Hume, S; Palmer, JL; Perez-Cruz, PE; Williams, JL; Yennurajalingam, S, 2013) |
| "Fatigue is the most common and often the most bothersome complaint of individuals who are treated for cancer." | 6.75 | Effect of methylphenidate on fatigue in women with recurrent gynecologic cancer. ( Block, I; Gold, MA; Johnson, RL; Markwell, S; Zupancic, M, 2010) |
| "In advanced cancer, the prevalence of fatigue is high and can be related to treatment or disease." | 6.75 | Pilot study to determine the optimal dose of methylphenidate for an n-of-1 trial for fatigue in patients with cancer. ( Carmont, SA; Hardy, JR; Mitchell, GK; Nikles, CJ; O'Shea, A; Schluter, P; Vora, R, 2010) |
| "Fatigue is a common complaint in patients with sarcoidosis." | 6.73 | Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. ( Baughman, RP; Harman, S; Lower, EE, 2008) |
| "Fatigue is a common nonmotor symptom in idiopathic Parkinson disease (IPD) that can prominently affect everyday function." | 6.73 | Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. ( Jog, MS; Mendonça, DA; Menezes, K, 2007) |
| "Asthenia (or fatigue) is one of the most common symptoms in palliative patients." | 6.49 | [Use of methylphenidate in palliative patients with asthenia: a review]. ( Palacio, P; Royo, P; Saralegui, A, 2013) |
| "Methylphenidate is a psychostimulant drug used to treat fatigue in patients with advanced cancer, for which there is no gold standard of treatment." | 5.51 | Improved cancer-related fatigue in a randomised clinical trial: methylphenidate no better than placebo. ( Centeno, C; Cuervo, MA; De Santiago, A; Gagnon, B; Gandara, A; Portela, MA; Ramos, D; Rojí, R; Salgado, E; Sanz, A, 2022) |
| " Methylphenidate had positive effects on self-reported fatigue as well as on declarative memory 24 hours after learning; caffeine had a positive effect on sustained attention; there was no significant effect of modafinil in any of the instruments of our test battery." | 5.41 | Cognitive enhancement effects of stimulants: a randomized controlled trial testing methylphenidate, modafinil, and caffeine. ( Bovy, L; Dresler, M; Kühn, S; Ohla, K; Repantis, D, 2021) |
| "Methylphenidate, modafinil, and amantadine are commonly prescribed medications for alleviating fatigue in multiple sclerosis; however, the evidence supporting their efficacy is sparse and conflicting." | 5.41 | Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. ( Aljarallah, S; Auvray, C; Cordano, C; Creasman, J; Jin, C; Krysko, K; Manguinao, M; McCulloch, C; Morris, B; Mowry, E; Nourbakhsh, B; Revirajan, N; Rutatangwa, A; Waubant, E, 2021) |
| "To evaluate the efficacy of methylphenidate as needed for the management of fatigue in patients with advanced cancer." | 5.34 | Methylphenidate as Needed for Fatigue in Patients With Advanced Cancer. A Prospective, Double-Blind, and Placebo-Controlled Study. ( Groenvold, M; Lund, L; Pedersen, L; Petersen, MA; Sjogren, P, 2020) |
| "The study is a randomized, placebo-controlled, crossover, four-sequence, four-period, double-blind, multicenter trial of three commonly used medications for the treatment of MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in fatigued subjects with MS." | 5.27 | Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial. ( Nourbakhsh, B; Revirajan, N; Waubant, E, 2018) |
| "The Fatigue and Sarcoidosis-Treatment with Methylphenidate study is a randomised, controlled, parallel-arm and feasibility trial of methylphenidate for the treatment of sarcoidosis-associated fatigue." | 5.24 | Feasibility study of a randomised controlled trial to investigate the treatment of sarcoidosis-associated fatigue with methylphenidate (FaST-MP): a study protocol. ( Atkins, C; Clark, AB; Fordham, R; Jones, AP; Stockl, A; Wilson, AM, 2017) |
| " Studies in early radiotherapy treatment phase (five studies) Pharmacological studies in the "early radiotherapy treatment phase" were designed to prevent or ameliorate cognitive deficits and included drugs used in dementia (memantine) and fatigue (d-threo-methylphenidate hydrochloride)." | 5.22 | Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation. ( Brown, PD; Day, J; Gehring, K; Grosshans, D; Kirkman, MA; Li, J; Taphoorn, M; Zienius, K, 2022) |
| "To investigate whether methylphenidate can alleviate fatigue, as measured by the Functional Assessment of Cancer Therapy: Fatigue subscale, in men with prostate cancer (PCa) treated with a luteinizing hormone-releasing hormone (LHRH) for a minimum of 6 months, and to assess changes in global fatigue and quality of life (QoL) as measured by the Bruera Global Fatigue Severity Scale (BFS) and the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), respectively." | 5.20 | Phase II, randomised, double-blind, placebo-controlled trial of methylphenidate for reduction of fatigue levels in patients with prostate cancer receiving LHRH-agonist therapy. ( Alibhai, SM; Bhatt, JR; Chahin, R; Fleshner, NE; Hersey, KM; Richard, PO, 2015) |
| "REASON FOR THE STUDY: Studies on methylphenidate for cancer-related fatigue showed conflicting results." | 5.19 | Use of methylphenidate for the management of fatigue in Chinese patients with cancer. ( Kwok, AO; Lam, PT; Law, M; Leung, TW; Liu, RK; Ng, KH; Siu, SW; Soong, IS; Wong, KH, 2014) |
| "Modafinil had no effect on cancer-related fatigue and should not be prescribed outside a clinical trial setting." | 5.19 | Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. ( Bahadori, R; Bates, N; Benepal, T; Blackhall, F; Dutton, S; Fife, K; O'Brien, M; Spathis, A; Stone, P; Wee, B; Wharton, R, 2014) |
| "To evaluate the response of fatigue and depression in patients with advanced illness to titrated doses of methylphenidate (MP) as compared with placebo." | 5.16 | Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial. ( Brazeau, DA; Brazeau, GA; Donnelly, JP; Drake, J; Kerr, CW; Milch, RA; Skretny, JA, 2012) |
| " Using an area under the serum concentration-time curve analysis, there was no evidence that methylphenidate, as compared with placebo, improved the primary end point of cancer-related fatigue in this patient population (P = ." | 5.14 | Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. ( Ali, A; Atherton, PJ; Barton, D; Dakhil, SR; Duane, SF; Griffin, PC; Johnson, DB; Loprinzi, CL; Moraska, AR; Silberstein, PT; Sloan, JA; Sood, A; Suh, JJ, 2010) |
| "This 6-week, randomized, double-blind, placebo-controlled design evaluated the efficacy of methylphenidate to treat fatigue in prostate cancer patients." | 5.14 | Methylphenidate for fatigue in ambulatory men with prostate cancer. ( Arauz, G; Breitbart, W; Morris, M; Nelson, C; O'Shea, N; Rosenfeld, B; Roth, AJ; Scher, H; Slovin, S, 2010) |
| "This study suggests that women with breast cancer who are suffering from moderate to severe fatigue may benefit from methylphenidate." | 5.12 | A phase II study of methylphenidate for the treatment of fatigue. ( Bhatia, S; Daggy, J; Einhorn, L; Hanna, A; Hanna, N; Mayer, ML; Monahan, P; Sledge, G, 2006) |
| "While our review suggests that some psychostimulants-particularly methylphenidate-appear well-tolerated and demonstrate some efficacy for depression, as well as fatigue and sleepiness, the strength of evidence in our estimates was low to very low for most agents given the small sample sizes, few RCTs, and imprecision in most estimates." | 5.12 | Comparative efficacy and safety of stimulant-type medications for depression: A systematic review and network meta-analysis. ( Bahji, A; Mesbah-Oskui, L, 2021) |
| "Fatigue scores fell significantly during methylphenidate intake in comparison with baseline (mean difference: -0." | 5.12 | Does methylphenidate reduce the symptoms of chronic fatigue syndrome? ( Blockmans, D; Bobbaers, H; Persoons, P; Van Houdenhove, B, 2006) |
| "To evaluate the effectiveness of patient-controlled methylphenidate as compared with placebo in cancer patients with fatigue, as measured by the Functional Assessment for Chronic Illness Therapy-Fatigue (FACIT-F)." | 5.12 | Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. ( Bruera, E; Driver, L; Palmer, JL; Shen, L; Valero, V; Willey, J; Zhang, T, 2006) |
| "To assess the effects of patient-controlled methylphenidate for cancer-related fatigue." | 5.10 | Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. ( Barnes, EA; Bruera, E; Driver, L; Escalante, C; Palmer, JL; Shen, L; Willey, J, 2003) |
| "To compare the efficacy of 2 psychostimulant medications, methylphenidate hydrochloride (Ritalin) and pemoline (Cylert), with a placebo intervention for the treatment of fatigue in patients with HIV disease." | 5.09 | A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. ( Breitbart, W; Funesti-Esch, J; Kaim, M; Rosenfeld, B, 2001) |
| "This review potentially supports the use of methylphenidate for opioid-induced sedation, cognitive decline and fatigue in cancer patients." | 4.98 | The Use of Methylphenidate for Physical and Psychological Symptoms in Cancer Patients: A Review. ( Andrew, BN; Guan, NC; Jaafar, NRN, 2018) |
| "Erythropoietin and methylphenidate significantly reduced fatigue severity in patients with cancer and in recipients of hsct." | 4.98 | Pharmacologic interventions for fatigue in cancer and transplantation: a meta-analysis. ( Cabral, S; Cataudella, D; Culos-Reed, N; Davis, H; Duong, N; Dupuis, LL; Gibson, F; Götte, M; Hinds, P; Nijhof, SL; Oberoi, S; Robinson, PD; Sung, L; Tomlinson, D; van der Torre, P, 2018) |
| " We included studies investigating pemoline and modafinil in participants with multiple sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue in meta-analysis." | 4.91 | Pharmacological treatments for fatigue associated with palliative care. ( Cuhls, H; Minton, O; Mücke, M; Peuckmann-Post, V; Radbruch, L; Stone, P, 2015) |
| "Although most research to date has focused on the use of methylphenidate for the relief of symptoms such as asthenia and depression in cancer patients, there is growing interest in the use of modafinil, a psychostimulant with a structure and mechanism that differs from other drugs belonging to this group." | 4.87 | The use of psychostimulants in cancer patients. ( Centeno, C; Portela, MA; Rubiales, AS, 2011) |
| " Studies investigating amantadine, pemoline, and modafinil in participants with Multiple Sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue could be used for meta-analysis." | 4.86 | Pharmacological treatments for fatigue associated with palliative care. ( Elsner, F; Krumm, N; Peuckmann, V; Radbruch, L; Trottenberg, P, 2010) |
| "In the absence of definitive evidence of effectiveness, trials of low-dose methylphenidate in medically ill adults with depression, fatigue, or apathy, with monitoring for response and adverse effects, are appropriate." | 4.85 | Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults. ( Hardy, SE, 2009) |
| "There is some evidence that treatment of cancer-related fatigue with methylphenidate appears to be effective." | 4.84 | A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. ( Hotopf, M; Minton, O; Richardson, A; Sharpe, M; Stone, P, 2008) |
| "Single therapy with methylphenidate or American ginseng contributes to the reduction in cancer-related fatigue (CRF) with different pharmacologic mechanisms and is relatively safe." | 3.88 | Single Institute Experience With Methylphenidate and American Ginseng in Cancer-Related Fatigue. ( Chang, YD; Davis, M; Kim, R; Oberoi-Jassal, R; Portman, D; Rajasekhara, S; Smith, J, 2018) |
| "To review recent evidence on the efficacy and safety of methylphenidate as a symptomatic treatment of patients with cancer-related fatigue (CRF)." | 3.85 | The use of methylphenidate to relieve fatigue. ( Centeno, C; Rojí, R, 2017) |
| "Methylphenidate has been shown to be an effective therapy in patients with refractory neurocardiogenic syncope." | 3.78 | Use of methylphenidate in the treatment of patients suffering from refractory postural tachycardia syndrome. ( Grubb, BP; Kanjwal, K; Kanjwal, Y; Karabin, B; Saeed, B, 2012) |
| "Response to methylphenidate is associated with higher baseline fatigue but not with higher baseline depression or sedation." | 3.77 | Factors associated with response to methylphenidate in advanced cancer patients. ( Bruera, E; Chacko, R; Palmer, JL; Yennurajalingam, S, 2011) |
| "Neurophysiologic measurements were made on a patient with multiple lung cancers and severe cancer-related fatigue (CRF) who responded to 5 mg methylphenidate twice daily, titrated to 10 mg twice daily after 2 weeks." | 3.74 | Combining objective and subjective outcomes in cancer-related fatigue: illustrations from a single case report. ( Davis, MP; Khoshknabi, DS; Kirkova, J; Ranganathan, VK; Siemionow, V; Walsh, D; Yue, GH, 2008) |
| "To examine the effect of exercise and methylphenidate on fatigue, functional ability, and cognitive function in patients with melanoma." | 3.71 | Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. ( Masood, N; Schwartz, AL; Thompson, JA, 2002) |
| " His progressively worsening excessive daytime sleepiness (EDS) was treated with methylphenidate hydrochloride." | 3.71 | Methylphenidate hydrochloride for excessive daytime sleepiness in a patient with myotonic dystrophy. ( Aizawa, C; Hirata, K; Miyamoto, M; Miyamoto, T; Suga, T; Takekawa, H, 2002) |
| "Methylphenidate and modafinil were equivalent to one another." | 3.01 | Cancer-related fatigue-pharmacological interventions: systematic review and network meta-analysis. ( Boldt, G; Bruera, E; Chiu, L; Chow, R; Lock, M; Prsic, E; Sanatani, M, 2023) |
| "Muscle fatigue is a disturbed homeostatic state characterized by a temporary inability to maintain force output and has lasting effects on the brain in the period immediately after exercise, such as decreased interhemispheric functional connectivity (FC)." | 2.87 | Methylphenidate alters brain connectivity after enhanced physical performance. ( Brooks, SJ; Ipser, J; King, M; Rauch, LH; Stein, DJ; van Breda, K, 2018) |
| "Fatigue is common in life-limiting cancer." | 2.80 | The Effect of Methylphenidate on Fatigue in Advanced Cancer: An Aggregated N-of-1 Trial. ( Carmont, SA; Currow, DC; Good, P; Hardy, JR; Mitchell, GK; Nikles, CJ; Schluter, PJ; Senior, HE, 2015) |
| "Methylphenidate dose was 5 mg every 2 hours as needed up to 20 mg per day." | 2.78 | Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial. ( Allo, JA; Bruera, E; Cohen, MZ; Frisbee-Hume, S; Palmer, JL; Perez-Cruz, PE; Williams, JL; Yennurajalingam, S, 2013) |
| "Methylphenidate (MPH) is an indirect dopamine and noradrenalin agonist, commonly used for the treatment of attention-deficit hyperactivity disorder for which it reduces undesirable behavior as evaluated by peers and authority figures, indicative of increased conformity." | 2.77 | Modulation of social influence by methylphenidate. ( Campbell-Meiklejohn, DK; Frith, CD; Gjerløff, T; Jensen, M; Møller, A; Roepstorff, A; Scheel-Kruger, J; Simonsen, A; Wohlert, V, 2012) |
| "In advanced cancer, the prevalence of fatigue is high and can be related to treatment or disease." | 2.75 | Pilot study to determine the optimal dose of methylphenidate for an n-of-1 trial for fatigue in patients with cancer. ( Carmont, SA; Hardy, JR; Mitchell, GK; Nikles, CJ; O'Shea, A; Schluter, P; Vora, R, 2010) |
| "Fatigue is the most common and often the most bothersome complaint of individuals who are treated for cancer." | 2.75 | Effect of methylphenidate on fatigue in women with recurrent gynecologic cancer. ( Block, I; Gold, MA; Johnson, RL; Markwell, S; Zupancic, M, 2010) |
| "Fatigue is a common nonmotor symptom in idiopathic Parkinson disease (IPD) that can prominently affect everyday function." | 2.73 | Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. ( Jog, MS; Mendonça, DA; Menezes, K, 2007) |
| "Fatigue is a common complaint in patients with sarcoidosis." | 2.73 | Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. ( Baughman, RP; Harman, S; Lower, EE, 2008) |
| " Therefore, three-times-a-day dosing should be considered for those children exhibiting ADHD symptoms in the evening." | 2.68 | Effects of late-afternoon methylphenidate administration on behavior and sleep in attention-deficit hyperactivity disorder. ( Abikoff, H; Blader, JC; Foley, CA; Kent, JD; Koplewicz, HS, 1995) |
| "Fatigue is a common symptom experienced by people with cancer and other long-term, non-malignant conditions." | 2.61 | The holistic management of fatigue within palliative care. ( Dean, A, 2019) |
| "Trial evidence for treating fatigue as a manifestation of sarcoidosis is limited and requires further investigation." | 2.55 | Managing fatigue in sarcoidosis - A systematic review of the evidence. ( Atkins, C; Wilson, AM, 2017) |
| "Asthenia (or fatigue) is one of the most common symptoms in palliative patients." | 2.49 | [Use of methylphenidate in palliative patients with asthenia: a review]. ( Palacio, P; Royo, P; Saralegui, A, 2013) |
| "Methylphenidate is a psychostimulant originally used for the treatment of attention-deficit disorder." | 2.48 | Methylphenidate: established and expanding roles in symptom management. ( Prommer, E, 2012) |
| "Fatigue is a highly prevalent and distressing symptom associated with significant psychological and functional morbidity and decreased quality of life among patients with cancer." | 2.46 | Psychostimulants for cancer-related fatigue. ( Alici, Y; Breitbart, W, 2010) |
| "Methylphenidate has been studied most and is effective and well tolerated despite common side effects." | 2.44 | Pharmacologic treatment options for cancer-related fatigue: current state of clinical research. ( Alici, Y; Breitbart, W, 2008) |
| "Methylphenidate has been studied most and seems to be effective and well tolerated despite common side effects." | 2.44 | Update on psychotropic medications for cancer-related fatigue. ( Alici-Evcimen, Y; Breitbart, W, 2007) |
| "Current treatments for fatigue include educating patients and caregivers about fatigue, applying etiology-specific treatments, utilizing nonpharmacologic interventions, and prescribing pharmacologic therapies." | 2.42 | Treatment of cancer-related fatigue: an update. ( Escalante, CP, 2003) |
| "Fatigue is among the most common, yet least understood, symptoms of multiple sclerosis (MS) [1." | 2.41 | Fatigue in multiple sclerosis. ( Christodoulou, C; Krupp, LB, 2001) |
| "Fatigue is a common symptom in many diseases and disorders and can reduce quality of life, yet lacks an adequate pharmacological intervention." | 1.51 | Evaluation of the effects of chemotherapy-induced fatigue and pharmacological interventions in multiple mouse behavioral assays. ( Cullen, MJ; Dougherty, JP; Gershengorn, MC; Springer, DA, 2019) |
| "refusal of food, apathy and congestive heart failure) resulted in recovery to a stable health condition and stabilization of dementia." | 1.46 | [Methylphenidate in a patient with Alzheimer's disease : Increase in drive and cardiac performance]. ( Schuhfried, G, 2017) |
| "A 64-year-old woman with metastatic rectal cancer is admitted to the acute palliative care unit of our cancer center because of debilitating fatigue." | 1.39 | Can you help me feel less exhausted all the time? ( de Raaf, PJ; van der Rijt, CC, 2013) |
| " Methylphenidate (MP) appears safe when used in the treatment of depression and fatigue in advanced cancer." | 1.36 | Methylphenidate side effects in advanced cancer: a retrospective analysis. ( Davis, MP; Khoshknabi, DS; Lasheen, W; Mahmoud, F; Rivera, N; Walsh, D, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (8.08) | 18.7374 |
| 1990's | 1 (1.01) | 18.2507 |
| 2000's | 29 (29.29) | 29.6817 |
| 2010's | 50 (50.51) | 24.3611 |
| 2020's | 11 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Chow, R | 1 |
| Bruera, E | 7 |
| Sanatani, M | 1 |
| Chiu, L | 1 |
| Prsic, E | 1 |
| Boldt, G | 1 |
| Lock, M | 1 |
| Manu, P | 1 |
| Kirkman, MA | 3 |
| Day, J | 3 |
| Gehring, K | 3 |
| Zienius, K | 3 |
| Grosshans, D | 3 |
| Taphoorn, M | 3 |
| Li, J | 3 |
| Brown, PD | 3 |
| Dean, A | 1 |
| Pedersen, L | 2 |
| Lund, L | 1 |
| Petersen, MA | 1 |
| Sjogren, P | 1 |
| Groenvold, M | 1 |
| Centeno, C | 3 |
| Rojí, R | 2 |
| Portela, MA | 2 |
| De Santiago, A | 1 |
| Cuervo, MA | 1 |
| Ramos, D | 1 |
| Gandara, A | 1 |
| Salgado, E | 1 |
| Gagnon, B | 1 |
| Sanz, A | 1 |
| Repantis, D | 1 |
| Bovy, L | 1 |
| Ohla, K | 1 |
| Kühn, S | 1 |
| Dresler, M | 1 |
| Nourbakhsh, B | 2 |
| Revirajan, N | 2 |
| Morris, B | 1 |
| Cordano, C | 1 |
| Creasman, J | 1 |
| Manguinao, M | 1 |
| Krysko, K | 1 |
| Rutatangwa, A | 1 |
| Auvray, C | 1 |
| Aljarallah, S | 1 |
| Jin, C | 1 |
| Mowry, E | 1 |
| McCulloch, C | 1 |
| Waubant, E | 2 |
| Bourdette, D | 1 |
| Atkins, C | 3 |
| Jones, A | 1 |
| Clark, AB | 2 |
| Stockl, A | 2 |
| Fordham, R | 2 |
| Wilson, AM | 3 |
| Belloni, S | 1 |
| Arrigoni, C | 1 |
| de Sanctis, R | 1 |
| Arcidiacono, MA | 1 |
| Dellafiore, F | 1 |
| Caruso, R | 1 |
| Bahji, A | 1 |
| Mesbah-Oskui, L | 1 |
| Andrew, BN | 1 |
| Guan, NC | 1 |
| Jaafar, NRN | 1 |
| Connell, CJW | 1 |
| Thompson, B | 1 |
| Turuwhenua, J | 1 |
| Srzich, A | 1 |
| Gant, N | 1 |
| King, M | 1 |
| van Breda, K | 1 |
| Rauch, LH | 1 |
| Brooks, SJ | 1 |
| Stein, DJ | 1 |
| Ipser, J | 1 |
| Jones, AP | 1 |
| Quinn, DK | 1 |
| Mayer, AR | 1 |
| Master, CL | 1 |
| Fann, JR | 1 |
| Tomlinson, D | 1 |
| Robinson, PD | 1 |
| Oberoi, S | 1 |
| Cataudella, D | 1 |
| Culos-Reed, N | 1 |
| Davis, H | 1 |
| Duong, N | 1 |
| Gibson, F | 1 |
| Götte, M | 1 |
| Hinds, P | 1 |
| Nijhof, SL | 1 |
| van der Torre, P | 1 |
| Cabral, S | 1 |
| Dupuis, LL | 1 |
| Sung, L | 1 |
| Boris, JR | 1 |
| Bernadzikowski, T | 1 |
| Dougherty, JP | 1 |
| Springer, DA | 1 |
| Cullen, MJ | 1 |
| Gershengorn, MC | 1 |
| Siu, SW | 1 |
| Law, M | 1 |
| Liu, RK | 1 |
| Wong, KH | 1 |
| Soong, IS | 1 |
| Kwok, AO | 1 |
| Ng, KH | 1 |
| Lam, PT | 1 |
| Leung, TW | 1 |
| Yennurajalingam, S | 3 |
| Palmer, JL | 4 |
| Perez-Cruz, PE | 1 |
| Frisbee-Hume, S | 1 |
| Allo, JA | 1 |
| Williams, JL | 1 |
| Cohen, MZ | 1 |
| Stone, PC | 2 |
| de Raaf, PJ | 1 |
| van der Rijt, CC | 1 |
| Saralegui, A | 1 |
| Palacio, P | 1 |
| Royo, P | 1 |
| Gong, S | 1 |
| Sheng, P | 1 |
| Jin, H | 1 |
| He, H | 1 |
| Qi, E | 1 |
| Chen, W | 1 |
| Dong, Y | 1 |
| Hou, L | 1 |
| Onishi, E | 1 |
| Biagioli, F | 1 |
| Safranek, S | 1 |
| Richard, PO | 1 |
| Fleshner, NE | 1 |
| Bhatt, JR | 1 |
| Hersey, KM | 1 |
| Chahin, R | 1 |
| Alibhai, SM | 1 |
| Spathis, A | 1 |
| Fife, K | 1 |
| Blackhall, F | 1 |
| Dutton, S | 1 |
| Bahadori, R | 1 |
| Wharton, R | 1 |
| O'Brien, M | 1 |
| Stone, P | 4 |
| Benepal, T | 1 |
| Bates, N | 1 |
| Wee, B | 1 |
| Ruddy, KJ | 1 |
| Barton, D | 2 |
| Loprinzi, CL | 2 |
| Radiloff, D | 1 |
| Zhao, Y | 1 |
| Boico, A | 1 |
| Blueschke, G | 1 |
| Palmer, G | 1 |
| Fontanella, A | 1 |
| Dewhirst, M | 1 |
| Piantadosi, CA | 1 |
| Noveck, R | 1 |
| Irwin, D | 1 |
| Hamilton, K | 1 |
| Klitzman, B | 1 |
| Schroeder, T | 1 |
| Denlinger, CS | 1 |
| Ligibel, JA | 1 |
| Are, M | 1 |
| Baker, KS | 1 |
| Demark-Wahnefried, W | 1 |
| Friedman, DL | 1 |
| Goldman, M | 1 |
| Jones, L | 1 |
| King, A | 1 |
| Ku, GH | 1 |
| Kvale, E | 1 |
| Langbaum, TS | 1 |
| Leonardi-Warren, K | 1 |
| McCabe, MS | 1 |
| Melisko, M | 1 |
| Montoya, JG | 1 |
| Mooney, K | 1 |
| Morgan, MA | 1 |
| Moslehi, JJ | 1 |
| O'Connor, T | 1 |
| Overholser, L | 1 |
| Paskett, ED | 1 |
| Raza, M | 1 |
| Syrjala, KL | 1 |
| Urba, SG | 1 |
| Wakabayashi, MT | 1 |
| Zee, P | 1 |
| McMillian, NR | 1 |
| Freedman-Cass, DA | 1 |
| Rizvi, SJ | 1 |
| Geraci, J | 1 |
| Ravindran, A | 1 |
| Kennedy, SH | 1 |
| Mitchell, GK | 2 |
| Hardy, JR | 2 |
| Nikles, CJ | 2 |
| Carmont, SA | 2 |
| Senior, HE | 1 |
| Schluter, PJ | 1 |
| Good, P | 1 |
| Currow, DC | 1 |
| Mücke, M | 1 |
| Cuhls, H | 1 |
| Peuckmann-Post, V | 1 |
| Minton, O | 4 |
| Radbruch, L | 3 |
| Qu, D | 1 |
| Zhang, Z | 1 |
| Yu, X | 1 |
| Zhao, J | 1 |
| Qiu, F | 1 |
| Huang, J | 1 |
| Schuhfried, G | 2 |
| Cameron, MH | 1 |
| McMillan, G | 1 |
| Mustian, KM | 1 |
| Alfano, CM | 1 |
| Heckler, C | 1 |
| Kleckner, AS | 1 |
| Kleckner, IR | 1 |
| Leach, CR | 1 |
| Mohr, D | 1 |
| Palesh, OG | 1 |
| Peppone, LJ | 1 |
| Piper, BF | 1 |
| Scarpato, J | 1 |
| Smith, T | 1 |
| Sprod, LK | 1 |
| Miller, SM | 1 |
| Chang, YD | 1 |
| Smith, J | 1 |
| Portman, D | 1 |
| Kim, R | 1 |
| Oberoi-Jassal, R | 1 |
| Rajasekhara, S | 1 |
| Davis, M | 1 |
| McNeil, C | 1 |
| Richardson, A | 3 |
| Sharpe, M | 3 |
| Hotopf, M | 3 |
| Khoshknabi, DS | 2 |
| Davis, MP | 2 |
| Ranganathan, VK | 1 |
| Siemionow, V | 1 |
| Walsh, D | 2 |
| Kirkova, J | 1 |
| Yue, GH | 1 |
| Ramsey, CS | 1 |
| Werchan, PM | 1 |
| Isdahl, WM | 1 |
| Fischer, J | 1 |
| Gibbons, JA | 1 |
| Breitbart, W | 5 |
| Alici, Y | 2 |
| Hardy, SE | 1 |
| Lasheen, W | 1 |
| Mahmoud, F | 1 |
| Rivera, N | 1 |
| Palshof, T | 1 |
| Schwartz, AL | 2 |
| Lower, EE | 2 |
| Fleishman, S | 1 |
| Cooper, A | 1 |
| Zeldis, J | 1 |
| Faleck, H | 1 |
| Yu, Z | 1 |
| Manning, D | 1 |
| Johnson, RL | 1 |
| Block, I | 1 |
| Gold, MA | 1 |
| Markwell, S | 1 |
| Zupancic, M | 1 |
| Kanjwal, K | 1 |
| Saeed, B | 1 |
| Karabin, B | 1 |
| Kanjwal, Y | 1 |
| Grubb, BP | 1 |
| Moraska, AR | 1 |
| Sood, A | 1 |
| Dakhil, SR | 1 |
| Sloan, JA | 1 |
| Atherton, PJ | 1 |
| Suh, JJ | 1 |
| Griffin, PC | 1 |
| Johnson, DB | 1 |
| Ali, A | 1 |
| Silberstein, PT | 1 |
| Duane, SF | 1 |
| Roth, AJ | 1 |
| Nelson, C | 1 |
| Rosenfeld, B | 2 |
| Scher, H | 1 |
| Slovin, S | 1 |
| Morris, M | 1 |
| O'Shea, N | 1 |
| Arauz, G | 1 |
| O'Shea, A | 1 |
| Vora, R | 1 |
| Schluter, P | 1 |
| Peuckmann, V | 1 |
| Elsner, F | 2 |
| Krumm, N | 1 |
| Trottenberg, P | 1 |
| Chacko, R | 1 |
| Rubiales, AS | 1 |
| Prommer, E | 1 |
| Kerr, CW | 1 |
| Drake, J | 1 |
| Milch, RA | 1 |
| Brazeau, DA | 1 |
| Skretny, JA | 1 |
| Brazeau, GA | 1 |
| Donnelly, JP | 1 |
| Campbell-Meiklejohn, DK | 1 |
| Simonsen, A | 1 |
| Jensen, M | 1 |
| Wohlert, V | 1 |
| Gjerløff, T | 1 |
| Scheel-Kruger, J | 1 |
| Møller, A | 1 |
| Frith, CD | 1 |
| Roepstorff, A | 1 |
| Sharp, V | 1 |
| Finlay, F | 1 |
| Kevitiyagala, D | 1 |
| Thompson, JA | 1 |
| Masood, N | 1 |
| Escalante, CP | 1 |
| BURKLEN, R | 1 |
| ZAPLETALEK, M | 1 |
| VOBORSKA, D | 1 |
| BARBORAKOVA, E | 1 |
| KOMENDA, S | 1 |
| TETREAULT, L | 1 |
| Driver, L | 2 |
| Barnes, EA | 1 |
| Willey, J | 2 |
| Shen, L | 2 |
| Escalante, C | 1 |
| Vale, S | 1 |
| Hanna, A | 1 |
| Sledge, G | 1 |
| Mayer, ML | 1 |
| Hanna, N | 1 |
| Einhorn, L | 1 |
| Monahan, P | 1 |
| Daggy, J | 1 |
| Bhatia, S | 1 |
| Wagner, MT | 1 |
| Marion, SD | 1 |
| Judson, MA | 1 |
| Blockmans, D | 1 |
| Persoons, P | 1 |
| Van Houdenhove, B | 1 |
| Bobbaers, H | 1 |
| Valero, V | 1 |
| Zhang, T | 1 |
| Reineke-Bracke, H | 1 |
| Devos, D | 1 |
| Krystkowiak, P | 1 |
| Clement, F | 1 |
| Dujardin, K | 1 |
| Cottencin, O | 1 |
| Waucquier, N | 1 |
| Ajebbar, K | 1 |
| Thielemans, B | 1 |
| Kroumova, M | 1 |
| Duhamel, A | 1 |
| Destée, A | 1 |
| Bordet, R | 1 |
| Defebvre, L | 1 |
| Mendonça, DA | 1 |
| Menezes, K | 1 |
| Jog, MS | 1 |
| Butler, JM | 1 |
| Case, LD | 1 |
| Atkins, J | 1 |
| Frizzell, B | 1 |
| Sanders, G | 1 |
| Griffin, P | 1 |
| Lesser, G | 1 |
| McMullen, K | 1 |
| McQuellon, R | 1 |
| Naughton, M | 1 |
| Rapp, S | 1 |
| Stieber, V | 1 |
| Shaw, EG | 1 |
| Mar Fan, HG | 1 |
| Clemons, M | 1 |
| Xu, W | 1 |
| Chemerynsky, I | 1 |
| Breunis, H | 1 |
| Braganza, S | 1 |
| Tannock, IF | 1 |
| Alici-Evcimen, Y | 1 |
| Harman, S | 1 |
| Baughman, RP | 1 |
| Branconnier, RJ | 1 |
| Cole, JO | 1 |
| Kent, JD | 1 |
| Blader, JC | 1 |
| Koplewicz, HS | 1 |
| Abikoff, H | 1 |
| Foley, CA | 1 |
| Kaim, M | 1 |
| Funesti-Esch, J | 1 |
| Krupp, LB | 1 |
| Christodoulou, C | 1 |
| LeGrand, SB | 1 |
| Sugawara, Y | 1 |
| Akechi, T | 1 |
| Shima, Y | 1 |
| Okuyama, T | 1 |
| Akizuki, N | 1 |
| Nakano, T | 1 |
| Uchitomi, Y | 1 |
| Miyamoto, T | 1 |
| Miyamoto, M | 1 |
| Suga, T | 1 |
| Aizawa, C | 1 |
| Takekawa, H | 1 |
| Hirata, K | 1 |
| Orzack, MH | 1 |
| Taylor, CL | 1 |
| Kornetsky, C | 1 |
| Franklin, KB | 1 |
| Herberg, LJ | 1 |
| Putnam, JS | 1 |
| Kaufman, LV | 1 |
| Michaels, RM | 1 |
| Canter, HG | 1 |
| Katz, S | 1 |
| Rapp, MS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Feasibility Study of Adjunctive Bright Light Therapy (BLT) for Amelioration of Fatigue in Chinese Cancer Patients Admitted to a Palliative Care Unit[NCT04525924] | 42 participants (Anticipated) | Interventional | 2020-08-01 | Recruiting | |||
| Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis[NCT03185065] | Phase 3 | 141 participants (Actual) | Interventional | 2017-10-04 | Completed | ||
| A PILOT STUDY OF INTRAVENOUS, SUBANESTHETIC DOSE OF KETAMINE VS PLACEBO, A CROSSOVER DESIGN, FOR MULTIPLE SCLEROSIS RELATED FATIGUE[NCT06064162] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| Fatigue in Sarcoidosis - A Feasibility Study Investigating the Treatment of Fatigue in Stable Sarcoidosis Patients Using Methylphenidate[NCT02643732] | 30 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | |||
| A Randomized Controlled Trial of Methylphenidate and a Nursing Telephone Intervention (NTI) for Fatigue in Advanced Cancer Patients[NCT00424099] | Phase 2/Phase 3 | 197 participants (Actual) | Interventional | 2007-01-09 | Completed | ||
| A Phase II, Randomized, Double-blind, Placebo Controlled Trial of Methylphenidate Hydrochloride for Reduction of Fatigue in Prostate Cancer Patients Receiving LHRH-Agonist Therapy[NCT00593853] | Phase 2 | 33 participants (Actual) | Interventional | 2008-01-31 | Terminated (stopped due to Slow Accrual) | ||
| Modafinil for the Treatment of Fatigue in Lung Cancer: a Multicentre, Randomised, Double-blinded, Placebo-controlled Trial[NCT00829322] | Phase 4 | 208 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Feasibility Study of a Hypnosis Intervention and a Cognitive Behavioral Therapy Intervention to Reduce Fatigue in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer[NCT04999306] | 60 participants (Anticipated) | Interventional | 2023-05-17 | Recruiting | |||
| Clinical Study on Wide Spectrum Micronutrients Supplementation in Patients With Cancer Related Fatigue During Adjuvant Chemotherapy[NCT06137833] | 92 participants (Anticipated) | Interventional | 2023-11-27 | Not yet recruiting | |||
| Conscious Dying/Conscious Living: Ketamine-Assisted Psychotherapy (KAP) for Patients at End of Life-A Pilot Study for Palliative and Hospice Care[NCT05214417] | Phase 2 | 120 participants (Anticipated) | Interventional | 2022-05-01 | Not yet recruiting | ||
| Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study[NCT00376675] | Phase 3 | 148 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Randomized Study Evaluating the Antiasthenic Effect of Methylphenidate (Ritalin) in Palliative Care in Cancer Patients[NCT00273741] | Phase 3 | 39 participants (Actual) | Interventional | 2007-01-31 | Terminated (stopped due to difficulty of recrutement) | ||
| Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentric Trial[NCT00914095] | Phase 4 | 69 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease: A Single Center, Randomized Pilot Study[NCT02879136] | Early Phase 1 | 42 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism[NCT03446807] | Phase 2 | 0 participants (Actual) | Interventional | 2021-12-31 | Withdrawn (stopped due to Sponsor Decision to terminate) | ||
| Randomized, Double-Blind, Placebo-Controlled Study of Dexmethylphenidate Hydrochloride, (d-MPH) in the Treatment of Fatigue in Sarcoidosis Subjects.[NCT00361387] | Phase 4 | 12 participants (Anticipated) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Participants will answer yes or no to this question: Taken into consideration the possible benefits and/or disadvantages of this medication, would you choose it, going forward to treat your MS fatigue?. The number of participants who answered Yes to this question is reported here." (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 39 |
| Amantadine | 41 |
| Modafinil | 55 |
| Methylphenidate | 55 |
ESS score during the fifth week of treatment period. The ESS score can range from 0 to 24. The higher the score, the higher that person's average sleep propensity in daily life, or their 'daytime sleepiness'. (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 9.4 |
| Amantadine | 9.3 |
| Modafinil | 8.3 |
| Methylphenidate | 8.8 |
MFIS score during the fifth week of treatment period. The total score of the MFIS ranges from 0 to 84. Higher scores denote more severe fatigue. (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 40.6 |
| Amantadine | 41.3 |
| Modafinil | 39.0 |
| Methylphenidate | 38.6 |
Neuro-QoL Item Bank - Fatigue T score during the fifth week of treatment period. T-score distributions rescale raw scores into standardized scores with a mean of 50 and a standard deviation (SD) of 10. Higher T-scores denote more severe fatigue. (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 53.1 |
| Amantadine | 53.0 |
| Modafinil | 52.5 |
| Methylphenidate | 52.0 |
The ESAS was used to assess the following 9 symptoms commonly experienced symptoms by cancer patients: pain, fatigue, nausea, depression, anxiety, drowsiness, dyspnea, anorexia, and well-being. Patients rate the intensity of their fatigue symptoms on a scale of 0 to 10 (0=not at all and 10=very much). Total ESAS fatigue score ranges from 0 to 10 with higher scores indicate higher fatigue. We measured the median change in ESAS fatigue score between Baseline and Day 15 using Kruskal-Wallis test. (NCT00424099)
Timeframe: Baseline and Day 15
| Intervention | score on a scale (Median) |
|---|---|
| Methylphenidate (MP) + Nursing Telephone Intervention (NTI) | -3.00 |
| Methylphenidate (MP) + Control Telephone Intervention (CTI) | -1.00 |
| Placebo (PL)+ Nursing Telephone Intervention (NTI) | -2.00 |
| Placebo (PL) + Control Telephone Intervention (CTI) | -2.00 |
FACIT-F fatigue subscale consists of 13 items. Patients rate the intensity of their fatigue symptoms on a scale of 0 to 4 (0=not at all and 4=very much). Total FACIT-F fatigue subscale score ranges from 0 to 52 with higher scores indicate higher fatigue. We measured the median change in FACIT-F fatigue sub scale score between Baseline and Day 15 using Kruskal-Wallis test. (NCT00424099)
Timeframe: Baseline and Day 15
| Intervention | score on a scale (Median) |
|---|---|
| Methylphenidate (MP) + Nursing Telephone Intervention (NTI) | 4.00 |
| Methylphenidate (MP) + Control Telephone Intervention (CTI) | 7.00 |
| Placebo (PL)+ Nursing Telephone Intervention (NTI) | 8.50 |
| Placebo (PL) + Control Telephone Intervention (CTI) | 5.00 |
"Perceived treatment efficacy was measured by the Subject Global Impression of Change (SGIC). The SGIC is a 3-point item in which the patient rates the change in the overall status since beginning the study drug (ranging from very much better, moderately better, a little better, about the same, a little worse, moderately worse, to very much worse). The average change in patient fatigue scores for those participants who express a perceived change of a little better via the SGIC scores were calculated. BFI usual fatigue item score was translated into 0 to 100 point scale for the analysis, with 0 (poor QOL or bad symptoms) and 100 (best QOL or no symptoms)." (NCT00376675)
Timeframe: Baseline and Week 4
| Intervention | Units on scale (Mean) |
|---|---|
| Methylphenidate | 31.0 |
| Placebo | 23.8 |
"Perceived treatment efficacy was measured by the Subject Global Impression of Change (SGIC). The SGIC is a 3-point item in which the patient rates the change in the overall status since beginning the study drug (ranging from very much better, moderately better, a little better, about the same, a little worse, moderately worse, to very much worse). The average change in patient fatigue scores for those participants who express a perceived change of a little better via the SGIC scores were calculated. BFI usual fatigue item score was translated into 0 to 100 point scale for the analysis, with 0 (poor QOL or bad symptoms) and 100 (best QOL or no symptoms)." (NCT00376675)
Timeframe: Baseline and Week 4
| Intervention | units on a scale (Mean) |
|---|---|
| Methylphenidate | 20.9 |
| Placebo | 15 |
"Perceived treatment efficacy was measured by the Subject Global Impression of Change (SGIC). The SGIC is a 3-point item in which the patient rates the change in the overall status since beginning the study drug (ranging from very much better, moderately better, a little better, about the same, a little worse, moderately worse, to very much worse). The average change in patient fatigue scores for those participants who express a perceived change of a little better via the SGIC scores were calculated. BFI usual fatigue item score was translated into 0 to 100 point scale for the analysis, with 0 (poor QOL or bad symptoms) and 100 (best QOL or no symptoms)." (NCT00376675)
Timeframe: Baseline and Week 4
| Intervention | Units on scale (Mean) |
|---|---|
| Methylphenidate | 20.0 |
| Placebo | 11.4 |
Pittsburgh Sleep Quality Index (PSQI) consists of 19 items and 7 scales. The AUC for the overall PSQI at baseline and at weeks 1-4 after being translated onto a 0 to 100 point scale was calculated. Higher scores are better. (NCT00376675)
Timeframe: Baseline to Week 4
| Intervention | units on a scale * weeks (Mean) |
|---|---|
| Methylphenidate | 144.37 |
| Placebo | 145.93 |
The SF-36 is a 36-item short form to measure health status in various populations. The vitality subscale is comprised of 4 items and is a measure of energy level as well as fatigue. The AUC for the vitality subscale at baseline and at weeks 1-4 after being translated onto a 0 to 100 point scale was calculated. Higher scores are better. (NCT00376675)
Timeframe: Baseline to Week 4
| Intervention | units on a scale * weeks (Mean) |
|---|---|
| Methylphenidate | 134.74 |
| Placebo | 121.59 |
"The prorated area under the curve (AUC) for the usual fatigue question of the BFI at baseline and at weeks 1-4 after being translated onto a 0 (poor quality of life (QOL) or bad symptoms) to 100 (best QOL or no symptoms) point scale was calculated as the following:~For those completed 4 weeks item: AUC/4;~For those completed up to week 3 item: (AUC * 4) / 3;~For those completed up to week 2 item: AUC * 2;~For those completed up to week 1 item: AUC * 4;~The prorated AUC scores were then transformed onto 0 to 100 point scale with 0 (poor QOL or bad symptoms) and 100 (best QOL or no symptoms) for analysis." (NCT00376675)
Timeframe: Baseline to week 4
| Intervention | units on a scale (Mean) |
|---|---|
| Methylphenidate | 50.33 |
| Placebo | 47.15 |
Area under the curve (AUC) for the other fatigue items of the BFI at baseline and at weeks 1-4 after being translated onto a 0 to 100 point scale was calculated. Higher scores are better. (NCT00376675)
Timeframe: Baseline to Week 4
| Intervention | units on a scale * weeks (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Fatigue right now | Worst fatigue last 24 hours | Fatigue interference with general activity | Fatigue interference with mood | Fatigue interference with walking ability | Fatigue interference with normal work | Fatigue interference with relations with others | Fatigue interference with enjoyment of life | |
| Methylphenidate | 179.96 | 144.59 | 187.60 | 205.31 | 210.09 | 179.94 | 224.72 | 194.15 |
| Placebo | 174.94 | 126.36 | 171.06 | 220.29 | 206.46 | 168.84 | 243.87 | 184.12 |
Linear Analogue Self Assessment (LASA) consists of 6 single-item numeric analogue scales. The AUC for the six-items at baseline and at weeks 1-4 after being translated onto a 0 to 100 point scale was calculated. Higher scores are better. (NCT00376675)
Timeframe: Baseline to Week 4
| Intervention | units on a scale * weeks (Mean) | |||||
|---|---|---|---|---|---|---|
| Overall QOL | Mental well-being | Physical well-being | Emotional well-being | Social activity | Spiritual well-being | |
| Methylphenidate | 204.21 | 227.04 | 188.13 | 203.65 | 189.68 | 231.24 |
| Placebo | 201.34 | 226.40 | 191.07 | 215.65 | 177.34 | 255.88 |
The Symptom Experience Diary (SED) consists of 12 items. All scores were translated onto a 0-100 point scale, with 0 represent poor quality of life (QOL) or bad symptom and 100 is best QOL or no symptoms.The change in severity of adverse events was calculated as subtracting the item scores at baseline from the scores at week 4. (NCT00376675)
Timeframe: Baseline and Week 4
| Intervention | units on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nervousness | Appetite decrease | Sex drive | Abdominal pain | Dizziness | Shakiness | Heartbeat | Vomiting | Headaches | Trouble sleeping | Fatigue distress | Fatigue control satisfaction | |
| Methylphenidate | -2.7 | -5.2 | -0.9 | -3.5 | -2.2 | -0.6 | -2.0 | -0.8 | -0.8 | 10.6 | 22.9 | 28.0 |
| Placebo | 9.5 | 6.6 | 9.8 | 3.6 | 2.1 | 1.4 | -1.6 | 0.4 | 3.9 | 11.1 | 15.8 | 23.2 |
27 reviews available for methylphenidate and Lassitude
| Article | Year |
|---|---|
Cancer-related fatigue-pharmacological interventions: systematic review and network meta-analysis.
Topics: Central Nervous System Stimulants; Fatigue; Humans; Methylphenidate; Modafinil; Neoplasms; Network M | 2023 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
The holistic management of fatigue within palliative care.
Topics: Central Nervous System Stimulants; Chronic Disease; Cognitive Behavioral Therapy; Complementary Ther | 2019 |
A systematic review of systematic reviews and pooled meta-analysis on pharmacological interventions to improve cancer-related fatigue.
Topics: Adult; Fatigue; Humans; Methylphenidate; Neoplasms; Systematic Reviews as Topic | 2021 |
Comparative efficacy and safety of stimulant-type medications for depression: A systematic review and network meta-analysis.
Topics: Adult; Central Nervous System Stimulants; Depression; Fatigue; Humans; Methylphenidate; Network Meta | 2021 |
The Use of Methylphenidate for Physical and Psychological Symptoms in Cancer Patients: A Review.
Topics: Analgesics, Opioid; Animals; Cancer Pain; Central Nervous System Stimulants; Cognitive Dysfunction; | 2018 |
Pharmacologic interventions for fatigue in cancer and transplantation: a meta-analysis.
Topics: Central Nervous System Stimulants; Erythropoietin; Fatigue; Hematopoietic Stem Cell Transplantation; | 2018 |
[Use of methylphenidate in palliative patients with asthenia: a review].
Topics: Asthenia; Dopamine Uptake Inhibitors; Fatigue; Humans; Methylphenidate; Palliative Care | 2013 |
Effect of methylphenidate in patients with cancer-related fatigue: a systematic review and meta-analysis.
Topics: Cognition; Depression; Fatigue; Humans; Methylphenidate; Neoplasms | 2014 |
Pharmacological treatments for fatigue associated with palliative care.
Topics: Adult; Amantadine; Benzhydryl Compounds; Carnitine; Central Nervous System Stimulants; Chronic Disea | 2015 |
Psychotropic drugs for the management of cancer-related fatigue: a systematic review and meta-analysis.
Topics: Benzhydryl Compounds; Fatigue; Humans; Methylphenidate; Modafinil; Neoplasms; Psychotropic Drugs | 2016 |
Managing fatigue in sarcoidosis - A systematic review of the evidence.
Topics: Adalimumab; Antirheumatic Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Exercise | 2017 |
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Cognitive Behavioral Therapy; Dexmethylphen | 2017 |
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Cognitive Behavioral Therapy; Dexmethylphen | 2017 |
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Cognitive Behavioral Therapy; Dexmethylphen | 2017 |
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Cognitive Behavioral Therapy; Dexmethylphen | 2017 |
A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue.
Topics: Anemia; Antidepressive Agents, Second-Generation; Antineoplastic Agents; Central Nervous System Stim | 2008 |
Pharmacologic treatment options for cancer-related fatigue: current state of clinical research.
Topics: Antidepressive Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Cholinesterase Inhib | 2008 |
Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Chronic Disease; Clinical Trials as Topic; Depressio | 2009 |
[Pharmaceutical treatment of cancer-associated fatigue--a survey of a Cochrane review].
Topics: Antidepressive Agents, Second-Generation; Central Nervous System Stimulants; Erythropoietin; Evidenc | 2009 |
Fatigue in long-term cancer survivors.
Topics: Adaptation, Psychological; Algorithms; Central Nervous System Stimulants; Exercise Therapy; Fatigue; | 2009 |
Drug therapy for the management of cancer-related fatigue.
Topics: Adult; Antidepressive Agents; Central Nervous System Stimulants; Darbepoetin alfa; Erythropoietin; F | 2010 |
Psychostimulants for cancer-related fatigue.
Topics: Central Nervous System Stimulants; Dextroamphetamine; Fatigue; Humans; Methylphenidate; Neoplasms; W | 2010 |
Pharmacological treatments for fatigue associated with palliative care.
Topics: Adult; Amantadine; Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Humans; Kidney | 2010 |
Psychostimulants for the management of cancer-related fatigue: a systematic review and meta-analysis.
Topics: Central Nervous System Stimulants; Clinical Trials as Topic; Fatigue; Humans; Methylphenidate; Neopl | 2011 |
The use of psychostimulants in cancer patients.
Topics: Adult; Antineoplastic Agents; Asthenia; Benzhydryl Compounds; Central Nervous System Stimulants; Chi | 2011 |
Methylphenidate: established and expanding roles in symptom management.
Topics: Analgesics, Opioid; Brain Neoplasms; Central Nervous System Stimulants; Cognition; Cognition Disorde | 2012 |
Treatment of cancer-related fatigue: an update.
Topics: Central Nervous System Stimulants; Exercise; Fatigue; Humans; Methylphenidate; Neoplasms; Quality of | 2003 |
Update on psychotropic medications for cancer-related fatigue.
Topics: Antidepressive Agents; Central Nervous System Stimulants; Dextroamphetamine; Fatigue; Humans; Methyl | 2007 |
Fatigue in multiple sclerosis.
Topics: Amantadine; Autoimmune Diseases; Benzhydryl Compounds; Brain; Case Management; Central Nervous Syste | 2001 |
35 trials available for methylphenidate and Lassitude
| Article | Year |
|---|---|
Methylphenidate as Needed for Fatigue in Patients With Advanced Cancer. A Prospective, Double-Blind, and Placebo-Controlled Study.
Topics: Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female; Humans; Methylphenidate; Ne | 2020 |
Improved cancer-related fatigue in a randomised clinical trial: methylphenidate no better than placebo.
Topics: Central Nervous System Stimulants; Double-Blind Method; Fatigue; Humans; Methylphenidate; Neoplasms; | 2022 |
Cognitive enhancement effects of stimulants: a randomized controlled trial testing methylphenidate, modafinil, and caffeine.
Topics: Adult; Attention; Caffeine; Central Nervous System Stimulants; Cognition; Double-Blind Method; Fatig | 2021 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Feasibility of investigating methylphenidate for the treatment of sarcoidosis-associated fatigue (the FaST-MP study): a double-blind, parallel-arm randomised feasibility trial.
Topics: Double-Blind Method; Fatigue; Feasibility Studies; Humans; Methylphenidate; Sarcoidosis | 2021 |
Effects of Dopamine and Norepinephrine on Exercise-induced Oculomotor Fatigue.
Topics: Adrenergic Uptake Inhibitors; Adult; Cross-Over Studies; Dopamine; Dopamine Uptake Inhibitors; Exerc | 2017 |
Methylphenidate alters brain connectivity after enhanced physical performance.
Topics: Adult; Brain; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female; Follow-Up Stu | 2018 |
Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial.
Topics: Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Fatigue; Hum | 2018 |
Feasibility study of a randomised controlled trial to investigate the treatment of sarcoidosis-associated fatigue with methylphenidate (FaST-MP): a study protocol.
Topics: Central Nervous System Stimulants; Chronic Disease; Double-Blind Method; England; Fatigue; Feasibili | 2017 |
Use of methylphenidate for the management of fatigue in Chinese patients with cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Central Nervous System Stimulants; Fatigue; Female; Hong Kong; | 2014 |
Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial.
Topics: Administration, Oral; Adult; Aged; Central Nervous System Stimulants; Counseling; Depression; Dopami | 2013 |
Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial.
Topics: Administration, Oral; Adult; Aged; Central Nervous System Stimulants; Counseling; Depression; Dopami | 2013 |
Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial.
Topics: Administration, Oral; Adult; Aged; Central Nervous System Stimulants; Counseling; Depression; Dopami | 2013 |
Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial.
Topics: Administration, Oral; Adult; Aged; Central Nervous System Stimulants; Counseling; Depression; Dopami | 2013 |
Phase II, randomised, double-blind, placebo-controlled trial of methylphenidate for reduction of fatigue levels in patients with prostate cancer receiving LHRH-agonist therapy.
Topics: Androgen Antagonists; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Humans; Male; | 2015 |
Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Carcinoma, Non-Small-Cell Lung; Central Nervous Syste | 2014 |
Predictors of response to adjunctive osmotic-release methylphenidate or placebo in patients with major depressive disorder: effects of apathy/anhedonia and fatigue.
Topics: Adolescent; Adult; Aged; Anhedonia; Apathy; Central Nervous System Stimulants; Depressive Disorder, | 2014 |
The Effect of Methylphenidate on Fatigue in Advanced Cancer: An Aggregated N-of-1 Trial.
Topics: Adult; Aged; Aged, 80 and over; Australia; Central Nervous System Stimulants; Cross-Over Studies; Do | 2015 |
Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Central Nervous System Stimulants; Dexmethylphenidat | 2009 |
Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Central Nervous System Stimulants; Dexmethylphenidat | 2009 |
Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Central Nervous System Stimulants; Dexmethylphenidat | 2009 |
Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Central Nervous System Stimulants; Dexmethylphenidat | 2009 |
Effect of methylphenidate on fatigue in women with recurrent gynecologic cancer.
Topics: Adult; Affect; Aged; Aged, 80 and over; Central Nervous System Stimulants; Fatigue; Female; Genital | 2010 |
Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial.
Topics: Aged; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female; Humans; Male; Methylp | 2010 |
Methylphenidate for fatigue in ambulatory men with prostate cancer.
Topics: Aged; Ambulatory Care; Blood Pressure; Central Nervous System Stimulants; Double-Blind Method; Fatig | 2010 |
Pilot study to determine the optimal dose of methylphenidate for an n-of-1 trial for fatigue in patients with cancer.
Topics: Aged; Aged, 80 and over; Central Nervous System Stimulants; Fatigue; Female; Humans; Male; Methylphe | 2010 |
Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Central Nervous System Stimulants; Depression; Double-Blind Method; Fatigue | 2012 |
Modulation of social influence by methylphenidate.
Topics: Adolescent; Adult; Analysis of Variance; Case-Control Studies; Central Nervous System Stimulants; Do | 2012 |
Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report.
Topics: Adult; Aged; Central Nervous System Stimulants; Fatigue; Female; Humans; Male; Methylphenidate; Midd | 2003 |
Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report.
Topics: Adult; Aged; Central Nervous System Stimulants; Fatigue; Female; Humans; Male; Methylphenidate; Midd | 2003 |
Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report.
Topics: Adult; Aged; Central Nervous System Stimulants; Fatigue; Female; Humans; Male; Methylphenidate; Midd | 2003 |
Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report.
Topics: Adult; Aged; Central Nervous System Stimulants; Fatigue; Female; Humans; Male; Methylphenidate; Midd | 2003 |
A phase II study of methylphenidate for the treatment of fatigue.
Topics: Adult; Aged; Breast Neoplasms; Central Nervous System Stimulants; Fatigue; Female; Humans; Indiana; | 2006 |
The effects of fatigue and treatment with methylphenidate on sustained attention in sarcoidosis.
Topics: Algorithms; Attention; Central Nervous System Stimulants; Fatigue; Female; Humans; Male; Methylpheni | 2005 |
Does methylphenidate reduce the symptoms of chronic fatigue syndrome?
Topics: Adult; Affect; Attention; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method | 2006 |
Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Fem | 2006 |
Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease.
Topics: Aged; Central Nervous System Stimulants; Dose-Response Relationship, Drug; Fatigue; Female; Gait Dis | 2007 |
Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease.
Topics: Aged; Central Nervous System Stimulants; Dose-Response Relationship, Drug; Fatigue; Female; Gait Dis | 2007 |
Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease.
Topics: Aged; Central Nervous System Stimulants; Dose-Response Relationship, Drug; Fatigue; Female; Gait Dis | 2007 |
Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease.
Topics: Aged; Central Nervous System Stimulants; Dose-Response Relationship, Drug; Fatigue; Female; Gait Dis | 2007 |
Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial.
Topics: Aged; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female; Humans; Male; Methylp | 2007 |
Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial.
Topics: Aged; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female; Humans; Male; Methylp | 2007 |
Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial.
Topics: Aged; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female; Humans; Male; Methylp | 2007 |
Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial.
Topics: Aged; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female; Humans; Male; Methylp | 2007 |
A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Brain Neoplasms; Central Nervous System Stimul | 2007 |
A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Central Nervous System Stimulants; Chemotherapy, Adjuvant; Cognition | 2008 |
Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue.
Topics: Adult; Aged; Central Nervous System Stimulants; Cross-Over Studies; Dexmethylphenidate Hydrochloride | 2008 |
Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue.
Topics: Adult; Aged; Central Nervous System Stimulants; Cross-Over Studies; Dexmethylphenidate Hydrochloride | 2008 |
Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue.
Topics: Adult; Aged; Central Nervous System Stimulants; Cross-Over Studies; Dexmethylphenidate Hydrochloride | 2008 |
Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue.
Topics: Adult; Aged; Central Nervous System Stimulants; Cross-Over Studies; Dexmethylphenidate Hydrochloride | 2008 |
Effects of late-afternoon methylphenidate administration on behavior and sleep in attention-deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Child, Preschool; Cross-Over S | 1995 |
A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease.
Topics: Ambulatory Care; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female; HIV Infect | 2001 |
A research report on the anti-fatigue effects of magnesium pemoline.
Topics: Adult; Attention; Caffeine; Central Nervous System; Central Nervous System Stimulants; Fatigue; Fema | 1968 |
37 other studies available for methylphenidate and Lassitude
| Article | Year |
|---|---|
Repurposing Drugs for Post-COVID-19 Fatigue Syndrome: Methylphenidate, Duloxetine, and Brexpiprazole.
Topics: COVID-19; Drug Repositioning; Duloxetine Hydrochloride; Fatigue; Humans; Methylphenidate; Quinolones | 2022 |
Are drugs for multiple sclerosis fatigue just placebos?
Topics: Amantadine; Double-Blind Method; Fatigue; Humans; Methylphenidate; Modafinil; Multiple Sclerosis; Ph | 2021 |
The use of methylphenidate to relieve fatigue.
Topics: Central Nervous System Stimulants; Fatigue; Humans; Meta-Analysis as Topic; Methylphenidate; Neoplas | 2017 |
Prolonged Postconcussive Symptoms.
Topics: Accidents, Traffic; Adaptation, Psychological; Anxiety Disorders; Attention; Axons; Brain Concussion | 2018 |
Therapy for fatigue and cognitive dysfunction in postural orthostatic tachycardia syndrome.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Central Nervous System Stimulan | 2018 |
Evaluation of the effects of chemotherapy-induced fatigue and pharmacological interventions in multiple mouse behavioral assays.
Topics: Analysis of Variance; Animals; Antimetabolites, Antineoplastic; Behavior, Animal; Body Weight; Centr | 2019 |
Methylphenidate in the management of cancer-related fatigue.
Topics: Central Nervous System Stimulants; Counseling; Fatigue; Female; Humans; Male; Methylphenidate; Neopl | 2013 |
Can you help me feel less exhausted all the time?
Topics: Central Nervous System Stimulants; Dexamethasone; Fatigue; Female; Humans; Methylphenidate; Middle A | 2013 |
FPIN's Clinical Inquiries. Methylphenidate for management of fatigue in the palliative care setting.
Topics: Central Nervous System Stimulants; Fatigue; Humans; Methylphenidate; Palliative Care; Treatment Outc | 2014 |
Laying to rest psychostimulants for cancer-related fatigue?
Topics: Benzhydryl Compounds; Carcinoma, Non-Small-Cell Lung; Central Nervous System Stimulants; Fatigue; Fe | 2014 |
Anti-hypotensive treatment and endothelin blockade synergistically antagonize exercise fatigue in rats under simulated high altitude.
Topics: Acclimatization; Altitude; Altitude Sickness; Animals; Cell Hypoxia; Disease Models, Animal; Dose-Re | 2014 |
Survivorship: cognitive function, version 1.2014.
Topics: Adaptation, Psychological; Benzhydryl Compounds; Brain Neoplasms; Central Nervous System Stimulants; | 2014 |
The Role of Methylphenidate in Cancer-Related Fatigue. Commentary on Mitchell et al.
Topics: Central Nervous System Stimulants; Fatigue; Humans; Methylphenidate; Neoplasms | 2015 |
[Methylphenidate in a patient with Alzheimer's disease : Increase in drive and cardiac performance].
Topics: Aged, 80 and over; Alzheimer Disease; Central Nervous System Stimulants; Critical Illness; Fatigue; | 2017 |
Methylphenidate is likely less effective than placebo for improving imbalance, walking, and fatigue in people with multiple sclerosis.
Topics: Adult; Central Nervous System Stimulants; Fatigue; Female; Humans; Male; Methylphenidate; Middle Age | 2017 |
Single Institute Experience With Methylphenidate and American Ginseng in Cancer-Related Fatigue.
Topics: Adult; Aged; Central Nervous System Stimulants; Complementary Therapies; Drug Therapy, Combination; | 2018 |
No rest for fatigue researchers.
Topics: Activities of Daily Living; Anemia; Antineoplastic Agents; Benzhydryl Compounds; Central Nervous Sys | 2008 |
Combining objective and subjective outcomes in cancer-related fatigue: illustrations from a single case report.
Topics: Central Nervous System Stimulants; Fatigue; Female; Humans; Lung Neoplasms; Methylphenidate; Middle | 2008 |
Acceleration tolerance at night with acute fatigue and stimulants.
Topics: Acceleration; Adaptation, Physiological; Adult; Aerospace Medicine; Amphetamine; Analysis of Varianc | 2008 |
Methylphenidate side effects in advanced cancer: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Akathisia, Drug-Induced; Anorexia; Central Nervous System Stimulants | 2010 |
Use of methylphenidate in the treatment of patients suffering from refractory postural tachycardia syndrome.
Topics: Adolescent; Adult; Central Nervous System Stimulants; Fatigue; Female; Follow-Up Studies; Humans; Ma | 2012 |
Challenge of managing cancer-related fatigue.
Topics: Central Nervous System Stimulants; Fatigue; Humans; Methylphenidate; Neoplasms | 2010 |
Factors associated with response to methylphenidate in advanced cancer patients.
Topics: Anorexia; Anxiety; Central Nervous System Stimulants; Depression; Drug Monitoring; Dyspnea; Fatigue; | 2011 |
Question 1: Is methylphenidate a useful treatment for cancer-related fatigue in children?
Topics: Brain Neoplasms; Central Nervous System Stimulants; Child; Fatigue; Humans; Male; Methylphenidate | 2013 |
Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate.
Topics: Adult; Aged; Antineoplastic Agents; Cancer Care Facilities; Central Nervous System Stimulants; Cogni | 2002 |
[A new central stimulant in states of psychic fatigue (psychasthenia)].
Topics: Central Nervous System Stimulants; Fatigue; Humans; Methylphenidate; Neurotic Disorders; Obsessive-C | 1957 |
[EFFECT OF PHENMETRAZINE AND RITALIN ON THE NEUROTIC FATIGUE SYNDROME].
Topics: Fatigue; Humans; Methylphenidate; Neurotic Disorders; Phenmetrazine; Syndrome | 1963 |
[COMPARATIVE EVALUATION OF THE SUBJECTIVE EFFECTS OF DEXTROAMPHETAMINE, METHYLPHENIDATE AND PLACEBO].
Topics: Appetite; Biomedical Research; Central Nervous System Stimulants; Dextroamphetamine; Double-Blind Me | 1964 |
Is methylphenidate an irreplaceable therapy for the fatigued cancer patient?
Topics: Central Nervous System Stimulants; Fatigue; Humans; Methylphenidate; Neoplasms | 2004 |
Treatment of fatigue: modafinil, methylphenidate, and goals of care.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Female; Germany; Humans; Me | 2006 |
The therapeutic role of methylphenidate in senile organic brain syndrome.
Topics: Aged; Anxiety; Confusion; Dementia; Depression; Double-Blind Method; Electroencephalography; Factor | 1980 |
Cancer fatigue--more data, less information?
Topics: Anemia; Central Nervous System Stimulants; Chronic Disease; Cytokines; Depression; Exercise; Fatigue | 2002 |
Efficacy of methylphenidate for fatigue in advanced cancer patients: a preliminary study.
Topics: Aged; Central Nervous System Stimulants; Fatigue; Female; Humans; Male; Methylphenidate; Middle Aged | 2002 |
Methylphenidate hydrochloride for excessive daytime sleepiness in a patient with myotonic dystrophy.
Topics: Adult; Central Nervous System Stimulants; Disorders of Excessive Somnolence; Evoked Potentials, Audi | 2002 |
Self-stimulation and catecholamines: drug-induced mobilization of the 'reserve'-pool re-establishes responding in catecholamine-depleted rats.
Topics: Animals; Catecholamines; Depression, Chemical; Fatigue; Male; Methamphetamine; Methylphenidate; Meth | 1974 |
Methylphenidate therapy in primary alveolar hypoventilation.
Topics: Aged; Cyanosis; Fatigue; Female; Humans; Hypercapnia; Hypoventilation; Hypoxia; Methylphenidate; Pul | 1973 |
Let the physician beware.
Topics: Depression; Fatigue; Humans; Methylphenidate; Substance-Related Disorders | 1970 |